EP Patent

EP3144393A1 — A synthetic pathway towards apremilast

Assigned to Lek Pharmaceuticals dd · Expires 2017-03-22 · 9y expired

What this patent protects

The present invention relates to an asymmetric process for providing N-{2-[(1 S )-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1 H -isoindol-4-yl}acetamide (apremilast) or a pharmaceutically acceptable salt or solvate thereof.

USPTO Abstract

The present invention relates to an asymmetric process for providing N-{2-[(1 S )-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1 H -isoindol-4-yl}acetamide (apremilast) or a pharmaceutically acceptable salt or solvate thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3144393A1
Jurisdiction
EP
Classification
—
Expires
2017-03-22
Drug substance claim
No
Drug product claim
No
Assignee
Lek Pharmaceuticals dd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.